Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers how the healthcare system will manage the tsunami of new patients resulting from increases in disease education and publicity.
A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect on collaborative efforts that advance patient care and outcomes in the field.
Maru Rinella, corresponding author for the recent expert panel recommendations on resmetirom, joins the Surfers to discuss key points of the recommendations and the rationale behind them.
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss some of the guidelines’ key goals and issues surrounding the screening, diagnosis and management of MASLD patients.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
EASL Secretary General Aleksander Krag and our other guests, Hannes Hagstrom and Michelle Long, join Jörn Schattenberg and Roger Green to discuss MASLD-related highlights of EASL Congress 2024.
SLD Think Tank 2023 co-chairs Jörn Schattenberg and Jeff Lazarus and participants Maja Thiele and Mike Betel join Louise Campbell and Roger Green to discuss high points of the recent Barcelona meting.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
This conversation focuses on why use of NITs is such a pivotal issue for MASH treatment and drug adoption, particularly if, as expected, the first MASH drug is approved this month.
